The Maudsley Prescribing Guidelines in Psychiatry (Anglais) Broché – 24 avril 2015
|Neuf à partir de||Occasion à partir de|
- Choisissez parmi 17 000 points de collecte en France
- Les membres du programme Amazon Prime bénéficient de livraison gratuites illimitées
- Trouvez votre point de collecte et ajoutez-le à votre carnet d’adresses
- Sélectionnez cette adresse lors de votre commande
Produits fréquemment achetés ensemble
Les clients ayant acheté cet article ont également acheté
Description du produit
Présentation de l'éditeur
The fully updated 12th edition of an essential reference for anyone responsible for prescribing drugs for patients with mental health disorders.
- A well–respected and widely–used source of information on which drugs to prescribe, which side effects to look out for, how best to augment or switch drugs, and more
- Provides concise reviews of psychiatric disorders and relevant psychopharmacology, along with general guidance based on the data reviewed and current clinical practice
- Includes specific guidance for schizophrenia, bipolar disorder, depression, anxiety, substance abuse, and special populations such as children, the elderly and pregnant women
- Each section features a full reference list so the evidence base can be checked quickly and easily
Quatrième de couverture
The essential reference for anyone responsible for prescribing drugs for patients with mental health disorders.
Widely and regularly used, it is the place to check for all relevant information on which drugs to prescribe, which side effects to look out for and how best to augment or switch drugs, such as antipsychotics, antidepressants and anxiolytics.
This 12th Edition provides brief but detailed reviews of psychiatric disorders and relevant psychopharmacology, with general guidance based on the data reviewed and current clinical practice. Sections cover plasma monitoring, schizophrenia, bipolar disorder, depression, anxiety, children and adolescents, substance abuse and special patient groups. Each section has a full reference list so that the evidence base can be checked quickly, if required. It also covers prescribing drugs outside their licensed indications and their interaction with substances such as alcohol, nicotine and caffeine.
Trainees will gain important information regarding the rational, safe and effective use of medications for patients with mental illness. Experienced clinicians will find excellent guidance regarding more complex issues that they may not encounter regularly.
Praise for previous editions:
An excellent book and a must for practising psychiatrists not only will the rational prescribing of psychotropic drugs drastically improve, but, more importantly, the patient will certainly benefit.
I would regard this book as mandatory for any pharmacist directly involved in the care of patients with a psychiatric diagnosis, be they primary or secondary care–based.
The Pharmaceutical Journal
This comprehensive guide will help nurses to be confident, sensitive and informed when discussing medication with patients and relatives, exploring treatment options within their professional teams and liaising with allied health professionals.
Aucun appareil Kindle n'est requis. Téléchargez l'une des applis Kindle gratuites et commencez à lire les livres Kindle sur votre smartphone, tablette ou ordinateur.
Pour obtenir l'appli gratuite, saisissez votre numéro de téléphone mobile.
Détails sur le produit
Si vous vendez ce produit, souhaitez-vous suggérer des mises à jour par l'intermédiaire du support vendeur ?
Quels sont les autres articles que les clients achètent après avoir regardé cet article?
Meilleurs commentaires des clients
My first one whas the 7th edition, which I discovered by chance as an intern.
The major benefit of the book would be the tables, flowcharts and recommendations. It's not a book for those who seek a theoretical base (Stahl's books are perhaps better in that regard), but it provides a lot of good practical tips. Whenever there is little evidence available, treatment with limited evidence (eg 1 RCT, no meta-analysis) are reported. They also mention non-evidence based (mostly, no systematic investigation) options, which provide additional options when everything else fails.
Unfortunately, sometimes topics were not discussed, but I'm glad to see that with increasing editions, more topics are covered. Generally, when they discuss something, you will be able to "do" something in daily practice with the recommendations.
In general, this book remains my #1 recommendation for interns and young residents, as they will find a lot of useful tips in it.
Commentaires client les plus utiles sur Amazon.com
... IF THE MOTHER TOOK IT WHILE SHE WAS PREGNANT. IT IMPLIES THAT LITHIUM IS WORSE. USE IT IF YOU GET SUED FOR PRESCRIBING SODIUM VALPROATE TO A WOMAN/GIRL WHO GETS PREGNANT. NEVER PRESCRIBE TO SOMEONE WHO MIGHT GET PREGNANT. 50% OF PREGNANCIES ARE ACCIDENTAL. Great book. Complements Stahl's Prescriber's Guide very well. Does have some odd moments, however.
1. Says on page 16 that "clozapine and quetiapine are 'fully' atypical, seemingly having no propensity whatever for EPS." Tell that to all the people I have given akathisia to from quetiapine.
2. Says on page 28 that 10 mg per day of olanzapine is an optimum dose. Not in my experience. But, of course, I am as susceptible to bias as anyone else. Says on page 52 that the effective dose range for olanzapine is 20 to 40 mg per day.
3. Says on page 102 that the signs and symptoms of NMS are fever, diaphoresis, rigidity, confusion, fluctuating LOC, fluctuating blood pressure, tachycardia, elevated CK, leukocytosis, altered liver function tests. The clinical findings are the same as for SS, therefore. The NEJM published a review article about SS. (352:11, March 17, 2005). It said that SS caused mydriasis, increased bowel sounds, increased muscle tone, hyperreflexia and agitation. It said that NMS did not affect the pupils, caused decreased bowel sounds, lead pipe rigidity, decreased reflexes and stupor. I know it is not a book about clinical signs, but still.
"only clozapine and quetiapine are 'fully' atypical, seemingly having no propensity whatever for EPS." (line 6 and 7, page 16). But, I frequently give people akathisia with quetiapine, but never Parkinsonism.
"Olanzapine 10 mg"
Surely adding aripiprazole reversed the side effects of haloperidol and risperidone because it binds more tightly to the receptor? (Second paragraph, page 37).
Why, on earth, would you state that results "imply" causation with death with people on one antispsychotic vs. three? Surely, illness severity is what is at play here?
Olanzapine dose: 10 mg (page 28), and 20-40 mg (page 52)?
You quoted Kinon, 2005 (page 38), as saying that there was no difference in severity of psychosis. There was no difference in weight gain either, so the amount that the patients actually took was what, exactly? (The 40 mg dose gained a little less than the 20 mg group).
Page 46: "Ideally, offer and ECG at least yearly." Page 100: "ECG monitoring is essential for all patients prescribed antipsychotics... on admission... yearly."
Page 102: the signs of NMS that are listed are insufficient to distinguish between different presentations like NMS. Hyperthermia and muscle rigidity can be delayed (Picard et al, "Atypical Neuroleptic Malignant Syndreom: Diagnostic Controversies and Considerations, 2008), There was a review in the NEJM that said that all, or all but one, of the listed signs and symptoms also occurs in serotonin syndrome, anticholinergic toxicity and malignant hyperthermia. Serotonin syndrome was the one with ALL the listed signs and symptoms.
Page 114: if someone has an QTc of greater than 500 msec, "Stop suspected causative drugs(s)". That is simply bad advice. What if the patient needs that particular drug?
PLEASE tell people, on page 199, to never prescribe sodium valproate to women of child-bearing age. You do say to look at chapter 7, but why would someone do that if they do not intend the patient to get pregnant, and the warning for lithium is stronger! The box on page 7.9 implies that the risk with lithium is greater than the risk with valproate. If the mother takes sodium valproate during pregnancy THERE IS A 30% RISK OF THE CHILD HAVING INTELLECTUAL DISABILITY. This dwarfs the risks for lithium, for example. You have pages and pages about QTc, why leave this out?
You need to include information about secondary and teriatry amine TCA's and the half lives of different benzos.
Please encourage the early use of depots and to have people on antispchotics for longer than a year after first episode schizophrenia!
Rechercher des articles similaires par rubrique